Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00570908 · ClinicalTrials.gov registry record · Phase 2
Brain Mets - Capecitabine Plus Sunitinib and WBRT
A Phase 2 study, sponsored by Baylor Breast Care Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00570908: Clinical Trial Phase 2 study, sponsored by Baylor Breast Care Center.
NCT00570908 is a Phase 2 study that was terminated before completion, run by Baylor Breast Care Center. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00570908, a Phase 2 study, was terminated before completion, sponsored by Baylor Breast Care Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of concurrent whole brain radiotherapy (WBRT) and capecitabine followed by combination capecitabine and sunitinib in treating patients with CNS metastases from breast cancer.
Primary Outcome
Progression free survival is defined as form initiation of WBRT with capecitabine to the time of first documented progression at any site (CNS or non-CNS site) or death due to any cause, where progression is defined stringently by progression in either CNS or extra-CNS metastases.
Interventions
- DRUG capecitabine
- DRUG sunitinib
- RADIATION WBRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-02 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Why NCT00570908 stopped before completion
NCT00570908 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 3 interventions - of which capecitabine is the first listed.
NCT00570908 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00570908 about?
NCT00570908 is a clinical study titled "Brain Mets - Capecitabine Plus Sunitinib and WBRT". The purpose of this study is to assess the efficacy and safety of concurrent whole brain radiotherapy (WBRT) and capecitabine followed by combination capecitabine and sunitinib in treating patients with CNS metastases from breast cancer.
What is the current status of trial NCT00570908?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2009-02. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00570908?
The interventions under investigation include: capecitabine (DRUG), sunitinib (DRUG), WBRT (RADIATION).
Who is sponsoring clinical trial NCT00570908?
This trial is sponsored by Baylor Breast Care Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00570908's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia